Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946438 · ClinicalTrials.gov registry record · Phase 4
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 208
- Enrollment target
NCT01946438 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 208 participants.
The verdict
NCT01946438, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 208 participants
- Enrollment target
Study Summary
The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and Fluzone Intradermal vaccines in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65 years of age. Primary Objective: * To describe the safety of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone Intradermal vaccines in adults 18 to \< 65 years of age and the safety of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65 years of age. Observational objectives: * To describe the immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone Intradermal vaccines in adults 18 to \< 65 years of age and the immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65 years of age. * To evaluate the compliance, in terms of immunogenicity, of each study vaccine (Fluzone Quadrivalent, Fluzone Intradermal, and Fluzone High-Dose) in the applicable age group with the historical requirements of the Committee for Human Medicinal Products (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96. * To submit sera from selected subjects to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.
Interventions
- BIOLOGICAL Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
- BIOLOGICAL Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),
- BIOLOGICAL Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946438
The ClinicalTrials.gov registry entry for NCT01946438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation), is the first listed.
NCT01946438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946438 about?
NCT01946438 is a clinical study titled "Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults". The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and Fluzone Intradermal vaccines in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65 years of age. Primary Objec...
What is the current status of trial NCT01946438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 208 participants. The study started on 2013-09. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01946438?
The interventions under investigation include: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation), (BIOLOGICAL), Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation), (BIOLOGICAL), Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01946438?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.